Issue 75

Filament Health and naturally extracted psychedelic medicines

Psilocybin has been found in hundreds of varieties of fungi, but Oregon is proposing that only one mushroom species – psilocybe cubensis – will be allowed in its regulated framework.

As with other psilocybin-producing mushrooms, psilocybe cubensis contains a number of different psychoactive compounds, including psilocin, baeocystin and norbaeocystin, which are far less understood and are thought to have symbiotic effects with psilocybin.

Filament Health is leading research into the mechanisms of these compounds, and CEO Benjamin Lightburn will outline evidence for multiple active metabolites working synergistically at PSYCH Symposium: London 2022.

PSYCHEDELIC MEDICINES MAY EASE CANCER PATIENTS' DEPRESSION AND ANXIETY

Over 90 clinical trials with psilocybin are being conducted in the US alone, with researchers exploring its efficacy in end-of-life care.

NEW SPECIES OF HALLUCINOGENIC MUSHROOM DISCOVERED IN AUSTRALIA

Researchers from the University of Queensland claim to have found evidence of a new psilocybin-producing fungi in soil samples.

BUSINESS AND INVESTMENT

Filament Health announces 2021 financial results.

Enveric Biosciences reports 2021 financial results.

Field Trip issued with patent for FT-104.

Beckley Psytech doses first volunteer with intranasal 5-MeO-DMT.

Four reasons why psychedelic healthcare could become mainstream.

PSYCH Symposium: London 2022

PSYCH Symposium brings leading figures from policy, science and business together to shape the future of psychedelic healthcare in Europe.

Speakers include:

Robert Barrow – CEO, MindMed
Benjamin Lightburn – CEO, Filament Health
Matthias Liechti – Professor of clinical pharmacology, University of Basel

Secure your ticket today to connect with industry influencers and learn from the sector’s thought leaders, as we expedite access to psychedelic medicine.

For partnership opportunities, please visit the website.

Ticket registration

SCIENCE AND RESEARCH

Officials acknowledge difficulty of psychedelic research in the US.

Berkeley Center for the Science of Psychedelics launches fellowship programme.

REGULATION AND LEGISLATION

Maryland lawmakers discuss psychedelic research fund.

With vote looming in Colorado, lawmakers postpone policy review.